drugset / Trial / NCT02944734

Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension

NCT02944734

Phase 2 Completed 392 enrolled Shin Poong Pharmaceutical Co. Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to explore the optimal dose of fixed-dose combination of candesartan cilexetil and amlodipine besylate by examining the safety and efficacy of the combination therapy compared to each of the monotherapy in patients with essential hypertension.

Timeline

Start
2014-09
Primary completion
2015-12
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified 5 mg Oral
Subject Amlodipine Other / unclassified 10 mg Oral
Subject Candesartan cilexetil Unknown 8 mg Oral
Subject Candesartan cilexetil Unknown 16 mg Oral